High doses of EPO, which are needed to achieve higher target hemoglobin levels, may be associated with an increased risk of brain hemorrhage, infarction and other events in MHD patients without any associated significant improvement in quality of life (Singh et al., 2006). The gene discussed is EPO; the disease is intracranial hemorrhage.